Abstract: The disclosure features macrocyclic compounds, alone and in combination with other therapeutic agents, as well as pharmaceutical compositions and protein complexes thereof, capable of modulating biological processes including RAS and RAS-RAF inhibition, and their uses in the treatment of cancers.

Abstract: A method for reinforcing soft ground by post-grouting combined with pressurized vacuum preloading is proposed, by pre-burying prefabricated vertical drains and air-boosted pipes in granular material piles, and the air-boosted pipes are used as grouting pipes to reduce the number of times of piling, which not only improves the construction efficiency, but also reduces the structural disturbance of the soil and the influence of smear effect, thus reducing the impact on the radial permeability and the radial consolidation coefficients. The method does not use geotextile bags for granular materials, which can avoid the problem of forming a localized clogging area around the geotextile bags, and the method not only improves the efficiency of vacuum transfer in a pre-consolidation stage, but also improves the grouting effect in the later stage, effectively enhances the strength of soft soil and makes granular material piles and the surrounding soil form composite ground.

Abstract: The present disclosure provides a comparator including a non-volatile memory device. The comparator is configured to compare an analog input voltage and a reference voltage and produce a digital output indicative of the comparison result. The digital output may represent a resistance state of the non-volatile memory device in response to the application of the reference voltage and the analog input voltage to the comparator. The present disclosure further provides analog-to-digital converters (ADCs) utilizing the comparator. The non-volatile memory device includes, for example, a memristor device, an MRAM (Magnetoresistive random access memory) device, a phase-change memory (PCM) device, a floating gate, a spintronic device, etc.

Abstract: The present disclosure provides a voltage divider circuit utilizing non-volatile memory devices. The non-volatile memory device may include, for example, a memristor device, an MRAM (Magnetoresistive random access memory) device, a phase-change memory (PCM) device, a floating gate, a spintronic device, etc. The voltage divider circuit may include one or more first non-volatile memory devices that form a resistor ladder. The resistor ladder may produce a plurality of reference voltages when the resistor ladder is connected between two voltages.

Abstract: The present invention “A polypeptide EXP and its drug delivery system as well as extracellular vesicle extraction kit thereof” belongs to the field of biomedical engineering and diagnostics. The amino acid sequence of the polypeptide EXP is set forth in SEQ ID NO. 1. Based on the polypeptide EXP, the present invention also provides a drug delivery system, targeted drug delivery system, enhanced drug delivery vehicle, a drug with enhanced delivery, targeted drug, extracellular vesicle extraction kit, disease diagnostic kit, a method for purifying extracellular vesicles, and use of the polypeptide EXP in pharmacy and diagnostic reagent manufacture.

Abstract: The photovoltaic module includes multiple cell sheets arranged in an array including multiple rows and multiple columns, where each of the multiple rows of cell sheets is arranged at intervals along a first direction, each of the multiple columns of cell sheets is arranged at intervals along a second direction, and each of the multiple cell sheets has a first surface and a second surface. The photovoltaic module further includes a first flexible cover layer located on a side of the first surface of each of the multiple cell sheets, and a second flexible cover layer located on a side of the second surface of each of the multiple cell sheets. The photovoltaic module is configured to be folded along a gap between two adjacent rows of cell sheets or along a gap between two adjacent columns of cell sheets with the folding angle of 0 degree to 180 degrees.

Abstract: The photovoltaic module includes multiple cell sheets arranged in an array including multiple rows and multiple columns. Each of the multiple rows of cell sheets is arranged at intervals along a first direction, each of the multiple columns of cell sheets is arranged at intervals along a second direction. The photovoltaic module includes multiple support plates arranged at intervals, where each of the multiple support plates extends along a direction in which each of the multiple rows or multiple columns of cell sheets is arranged, and each of the multiple support plates is arranged on the second surface of each of the multiple rows or the multiple columns of cell sheets. The photovoltaic module further includes a first flexible cover layer arranged on a side of the first surface of each of the multiple cell sheets and a second flexible cover layer arranged on each of the multiple support plates.

Abstract: Disclosed are bifunctional targeted protein autophagy degraders that comprise: 1) a small-molecule targeting a protein of interest; 2) a linker; and 3) a small-molecule recruiter of the autophagy adapter LC3B. These degraders target specific proteins for degradation through the autophagy-lysosomal degradation pathway.

Abstract: The present invention relates to an electrolyte comprising lithium difluoro(oxalate)borate (LiDFOB) and a carbonate solvent, wherein LiDFOB is present at a concentration in the range of 1.5 M to 3 M, a rechargeable battery comprising the electrolyte as described herein, a cathode layer, an anode layer and a separator, and a method of preparing the electrolyte as described herein, comprising the step of dissolving LiDFOB in a carbonate solvent, wherein LiDFOB is present at a concentration in the range of 1.5 M to 3 M.

Abstract: BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.

Abstract: A BRD9 protein degrading compound of structure or a pharmaceutically acceptable salt thereof is provided for the treatment of a disorder mediated by BRD9, including but not limited to abnormal cellular proliferation including cancer.

Abstract: BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.

Abstract: BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.

Abstract: Compounds that degrade BRD9 or MTH1 via the ubiquitin proteasome pathway in a subject in need thereof for therapeutic applications are provided. The compounds provided have an E3 Ubiquitin Ligase targeting moiety (Degron) that is linked to a Targeting Ligand for BRD9 or MTH1.

Abstract: The disclosure features macrocyclic compounds, alone and in combination with other therapeutic agents, as well as pharmaceutical compositions and protein complexes thereof, capable of modulating biological processes including RAS and RAS-RAF inhibition, and their uses in the treatment of cancers.

Abstract: Example implementations relate to translating a data structure to a video frame structure. For example, a computing device may perform a method of receiving analytic values of a data structure and converting the analytic values into raw pixel data such that each analytic value of the data structure is represented as a pixel in a video frame structure of pixels. The raw pixel data may be encoded into an I-frame in response to a determination that a difference between the raw pixel data and previous raw pixel data associated with previous analytic values exceeds a specified threshold. First data associated with at least one I-frame is retrieved in response to a request to view data changes exceeding the specified threshold.

Abstract: Techniques for optimized cell acquisition for long term evolution (LTE) time division duplex (TDD) systems or closed subscriber group (CSG)/evolved Multicast Broadcast Multimedia Service (eMBMS) capable user equipments (UEs) are disclosed. A UE obtains configuration information, CSG capability information, and/or eMBMS capability information for a cell. The UE also stores the obtained information for the cell in a cell information database. In some aspects, the UE may employ the CSG and/or eMBMS capability information to select a weaker cell, during initial frequency scan at power up of the UE, based on cell capability. Additionally or alternatively, the UE may employ the configuration information to determine an initial mutual information (Mi) hypothesis value for physical hybrid-automatic repeat request (HART) indicator channel (PHICH) group mapping of the cell.

Abstract: Certain aspects relate to methods and apparatus for obtaining system information by an apparatus comprising concurrently maintaining a first buffer for combining multiple transmissions of at least a first type of system information block (SIB) message across different system information (SI) message windows and a second buffer for combining multiple transmissions of at least a second type of SIB message within an SI window, and decoding at least first and second types of SIB messages based on contents in the first and second buffers.

Abstract: Techniques for optimized cell acquisition for long term evolution (LTE) time division duplex (TDD) systems or closed subscriber group (CSG)/evolved Multicast Broadcast Multimedia Service (eMBMS) capable user equipments (UEs) are disclosed. A UE obtains configuration information, CSG capability information, and/or eMBMS capability information for a cell. The UE also stores the obtained information for the cell in a cell information database. In some aspects, the UE may employ the CSG and/or eMBMS capability information to select a weaker cell, during initial frequency scan at power up of the UE, based on cell capability. Additionally or alternatively, the UE may employ the configuration information to determine an initial mutual information (Mi) hypothesis value for physical hybrid-automatic repeat request (HART) indicator channel (PHICH) group mapping of the cell.

Abstract: Aryl substituted diazabicyclooctanes (DBO) compounds that inhibit ?-lactamases of class A, class C or class D and potentiate ?-lactam antibiotics are disclosed. In particular, this disclosure provides DBO compounds that, when used in the disclosed Synergy MIC Assay with a ?-lactam antibiotic at a fixed concentration have an MIC of 8 ?g/mL or less against one or more isogenic ?-lactamase expressing bacterial strains.